For research use only.

Catalog No.S3720 Synonyms: GFT505

Elafibranor Chemical Structure

Molecular Weight(MW): 384.49

Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.

Size Price Stock Quantity  
USD 97 In stock
USD 290 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PPAR Inhibitors

Biological Activity

Description Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
PPARα [1]
PPARδ [1]
In vitro

GFT505 is a novel PPAR modulator that shows a preferential activity on PPAR-α and concomitant activity on PPAR-δ[2].

Methods Test Index PMID
Western blot
p22phox / Nox-4 / LC3-II / Beclin-1 ; 

PubMed: 31321239     

SIRT1-activated and autophagy-mediated effects of elafibranor on 10% HFD-sera-increased oxidative stress and apoptosis in HK-2 cells. Proteins levels in HK-2 cell lysate. ‡p<0.05 versus NC-sera group; ∗p<0.05 versus V-group; #p<0.05 versus elaf-group; †p<0.05 versus rSIRT1 group.

In vivo Elafibranor (GFT505) is a dual PPARα/δ agonist that has demonstrated efficacy in disease models of nonalcoholic fatty liver disease (NAFLD)/NASH and liver fibrosis. In the rat, GFT505 concentrated in the liver with limited extrahepatic exposure and underwent extensive enterohepatic cycling. Elafibranor confers liver protection by acting on several pathways involved in NASH pathogenesis, reducing steatosis, inflammation, and fibrosis. GFT505 improved liver dysfunction markers, decreased hepatic lipid accumulation, and inhibited proinflammatory (interleukin-1 beta, tumor necrosis factor alpha, and F4/80) and profibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I, alpha 1, and collagen type I, alpha 2) gene expression[1].


Animal Research:[2]
- Collapse
  • Animal Models: hApoE2 KI and hApoE2 KI/PPAR-α KO mice
  • Dosages: 30 mg/kg
  • Administration: oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.66 mM)
Ethanol 76 mg/mL (197.66 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.49


CAS No. 923978-27-2
Storage powder
in solvent
Synonyms GFT505
Smiles CSC1=CC=C(C=C1)C(=O)\C=C\C2=CC(=C(OC(C)(C)C(O)=O)C(=C2)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04171752 Recruiting Drug: elafibranor Geriatrics|Healthy Genfit November 22 2019 Phase 1
NCT03883607 Recruiting Drug: Elafibranor 80mg|Drug: Elafibranor 120mg Non Alcoholic Steatohepatitis Genfit May 2 2019 Phase 2
NCT03844555 Recruiting Drug: Elafibranor Renal Impairment|Renal Insufficiency|Kidney Diseases|Pharmacokinetics Genfit February 28 2019 Phase 1
NCT03765671 Completed Drug: Elafibranor Hepatic Impairment|Liver Disease|Pharmacokinetics Genfit|Syneos Health|University of Miami December 12 2018 Phase 1
NCT02704403 Recruiting Drug: Elafibranor|Drug: Placebo Nonalcoholic Steatohepatitis (NASH) With Fibrosis Genfit March 2016 Phase 3
NCT02142127 Completed Drug: 14C-labelled GFT505 120 mg Healthy Genfit|SGS Life Sciences a division of SGS Belgium NV April 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PPAR Signaling Pathway Map

Related PPAR Products

Tags: buy Elafibranor|Elafibranor ic50|Elafibranor price|Elafibranor cost|Elafibranor solubility dmso|Elafibranor purchase|Elafibranor manufacturer|Elafibranor research buy|Elafibranor order|Elafibranor mouse|Elafibranor chemical structure|Elafibranor mw|Elafibranor molecular weight|Elafibranor datasheet|Elafibranor supplier|Elafibranor in vitro|Elafibranor cell line|Elafibranor concentration|Elafibranor nmr|Elafibranor in vivo|Elafibranor clinical trial|Elafibranor inhibitor|Elafibranor Metabolism inhibitor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID